#JournalClub by Dr Rumeysa Yalcinkaya, Ankara Etlik City Hospital, Türkiye. Study finds no long-term benefit of extended (13–14 day) vs. standard (5–6 day) antibiotics for hospitalised children with CAP. Short course remains effective.🔗 Read more: shorturl.at/sxJ4H
#JournalClub submission by @rcduguid, @thefrancis6, Dr Jen Yan & Dr Te-Yu Hung!
Phase 3 trial of #Ziresovir in infants with RSV showed reduced bronchiolitis scores & viral load, but clinical impact is unclear. More studies needed.🔗Read more: shorturl.at/PcdbX
Support our international colleagues as they present the next live @WSPID#journalclub in two weeks on 18/12 at 1am AEST. Aussie colleagues, although not ideal for a live attendance, if you register, you'll be sent the recording after the event. :)
It’s a wrap! What a great ANZPID Clinical meeting. Inspiring sessions and wonderful catch ups with old and new friends. Thank you Dr Angela Berkhout and Dr Sophie Wen for the amazing program. Looking forward to Sydney in 2025!
@angieberkhout @DrSophCHWen@ASIDANZ
Dr Ushma Wada (WA), Ms Sarah Risdale (QLD) and Dr Emma Goeman (NSW) sharing the programmatic role out and impact of Nirservimab in their respective states. 85% efficacy in preventing RSV hospitalisations in WA is cause for celebration
@ASIDANZ#IDTwitter#medtwitter
The experts are here! Insightful approaches to tricky congenital CMV cases from the perspectives of Dr Renuka Sekar (maternal foetal medicine), Dr Matthew Lynch (paediatric neurology) and A/Prof Julia Clark (paediatric ID)
@ASIDANZ#IDTwitter#medtwitter
Let’s get down to business! Great updates and robust discussions presented at the ANZPID business meeting led by our Chair Dr Brendan McMullan, including a plug for the new edition of the Blue Book presented by A/Prof Penelope Bryant
@ASIDANZ#IDTwitter#medtwitter
Dr Brendan McMullan delving into the benefits of short course early IV-oral antibiotic switch with the Homefree study
@ASIDANZ @brendanmcID #IDTwitter#medtwitter